• In late February 2026, Novavax reported Q4 2025 revenue of US$147.14 million and net income of US$17.53 million, marking a move from loss-making to profitable operations for both the quarter and full year.
• This earnings swing was heavily supported by partnership-driven milestone payments and improved cost efficiency, underscoring how its collaboration-led model is now a central driver of profitability.
• Next, we’ll examine how this partnership-fueled return to profitability reshapes Novavax’s investment narrative built around licensing and royalty streams.

Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.

Novavax Investment Narrative Recap

To own Novavax today, you need to believe its partnership‑centric model can turn milestone payments and royalties into a durable, higher‑margin business across multiple vaccines, not just COVID‑19. The Q4 2025 swing to a US$17.53 million profit and full‑year profitability reinforces that story, but it does not remove the central near‑term risk: Novavax’s heavy reliance on partners like Sanofi and Takeda to hit regulatory and commercial milestones on time.

The recent Pfizer license agreement for Novavax’s Matrix‑M adjuvant is especially relevant here. It adds another potential royalty and milestone stream on top of Sanofi and Takeda, and helps explain why the market reacted strongly when Q4 revenue reached US$147.14 million, well ahead of expectations. For investors watching catalysts, Pfizer’s use of Matrix‑M in up to two infectious disease programs directly ties Novavax’s short‑term earnings momentum to the progress of this newer partnership.

Yet, despite the return to profit, investors should still pay close attention to how dependent Novavax remains on a few key partners and products...

Novavax's narrative projects $348.5 million revenue and $55.9 million earnings by 2028.

Uncover how Novavax's forecasts yield a $13.78 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were expecting Novavax’s revenue to fall about 54% a year and earnings to shrink to around US$17.1 million by 2028, so this surprise profitability may eventually challenge that much more pessimistic view, especially if Matrix‑M partnerships scale as hoped.

Explore 6 other fair value estimates on Novavax - why the stock might be worth over 9x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Novavax research is our analysis highlighting 3 key rewards and 5 important warning signs that could impact your investment decision.
• Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.